丹娜生物
(920009)
| 流通市值：3.60亿 | | | 总市值：27.71亿 |
| 流通股本：1008.00万 | | | 总股本：7754.60万 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 118,141,959.57 | 54,035,723.96 | 242,282,883.91 | 171,946,500 |
| 营业收入 | 118,141,959.57 | 54,035,723.96 | 242,282,883.91 | - |
| 二、营业总成本 | 77,330,665.63 | 36,561,854.44 | 153,730,093.27 | - |
| 营业成本 | 17,349,303.02 | 7,778,885.69 | 35,066,407.45 | - |
| 税金及附加 | 1,348,319.58 | 725,597.85 | 3,108,158.13 | - |
| 销售费用 | 24,283,793.81 | 11,500,677.98 | 49,037,631.49 | - |
| 管理费用 | 14,850,185.98 | 7,155,652.85 | 32,160,795.12 | - |
| 研发费用 | 19,433,671.33 | 9,411,062.58 | 34,527,862.45 | - |
| 财务费用 | 65,391.91 | -10,022.51 | -170,761.37 | - |
| 其中:利息费用 | 48,446.54 | 22,379.63 | 106,424.28 | - |
| 其中:利息收入 | 111,002.07 | 74,731.46 | 305,937.36 | - |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 712,527.86 | 583,152.91 | 26,551.67 | - |
| 加:投资收益 | 4,739,621.98 | 2,034,703.72 | 8,524,567.69 | - |
| 资产处置收益 | 119,863.13 | 118,883.7 | 0 | - |
| 资产减值损失(新) | -208,754.65 | -178,673.08 | -690,801.92 | - |
| 信用减值损失(新) | -42,771.69 | -155,749.72 | -298,020.75 | - |
| 其他收益 | 1,082,625.68 | 334,889.94 | 14,794,249.55 | - |
| 营业利润平衡项目 | 0 | 0 | 0 | - |
| 四、营业利润 | 47,214,406.25 | 20,211,076.99 | 110,909,336.88 | 80,389,600 |
| 加:营业外收入 | 3,350,396.39 | 10,008.09 | 59,635 | - |
| 减:营业外支出 | 50,437.56 | 11,168.46 | 303,944.04 | - |
| 利润总额平衡项目 | 0 | 0 | 0 | - |
| 五、利润总额 | 50,514,365.08 | 20,209,916.62 | 110,665,027.84 | 80,158,900 |
| 减:所得税费用 | 4,607,810.31 | 1,888,398.86 | 12,922,034.63 | - |
| 六、净利润 | 45,906,554.77 | 18,321,517.76 | 97,742,993.21 | - |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 45,906,554.77 | - | 97,742,993.21 | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 45,906,554.77 | 18,321,517.76 | 97,742,993.21 | 70,807,500 |
| 扣除非经常损益后的净利润 | 37,626,245.19 | 15,833,845.78 | 78,438,590.91 | 56,603,600 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.78 | 0.33 | 2 | - |
| (二)稀释每股收益 | 0.78 | 0.33 | 2 | - |
| 九、综合收益总额 | 45,906,554.77 | 18,321,517.76 | 97,742,993.21 | - |
| 归属于母公司股东的综合收益总额 | 45,906,554.77 | - | 97,742,993.21 | - |
| 公告日期 | 2026-08-24 | 2026-04-29 | 2026-04-08 | 2025-10-20 |
| 审计意见(境内) | | | 标准无保留意见 | |